3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
12
Colorectal Neoplasms
9
Lung Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Colonic Neoplasms
3
Skin Neoplasms
2
Skin Diseases
2
Rectal Neoplasms
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Spinocerebellar Degenerations
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumor
1
Soft Tissue Neoplasms
1
Recurrence
1
Peripheral Nervous System Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Noonan Syndrome 5
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Spinocerebellar Degenerations
×
binimetinib
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts